Presence of glass particles has been reported through customer complaint. Administration of glass particulate, if present in an intravenous drug, poses a potential safety risk to patients. Case
The Phase I study is a single-center, double-blind trial designed to evaluate the safety and tolerability of AG-348 through dose escalation in healthy adult men and women. The
According to Akorn, this acquisition will boost the company to transform into a larger, more diversified generic player. The acquisition will also bring critical mass and scale to
GOG-3003 (NCT01666444) is one of the two Phase II clinical trials of VTX-2337 currently in progress. The Phase II GOG-3003 study is being conducted in collaboration with the
According to GSK, this is the first marketing approval granted for Incruse Ellipta anywhere in the world. Incruse Ellipta is GSK’s first long-acting muscarinic antagonist (LAMA) monotherapy, a
The average age of an AML patient is 65-70 years and the currently recommended standard of care is intensive chemotherapy, but many patients due to age and co-morbidities
The drug is indicated for the control of serum phosphorus in patients with chronic kidney disease on dialysis. As part of a settlement agreement, Genzyme agreed to grant
The two Phase IIb clinical studies were double-blind, pioglitazone-controlled, dose-ranging studies designed to assess the safety, efficacy and tolerability of multiple remogliflozin etabonate doses for 12-weeks in treatment-naïve
Both Calima and Sirocco are the multinational trials that have been already started by AstraZeneca and MedImmune, the licensee of benralizumab. The company is participating in these trials
Currently, the company is carrying out a Phase II trial to show the clinical efficacy of Oxabact, in Primary Hyperoxaluria (PH), a rare autosomal recessive disorder leading to
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.